Alcon Inc. (ALC)

USD 84.74

(-0.94%)

EBITDA Summary of Alcon Inc.

  • Alcon Inc.'s latest annual EBITDA in 2023 was 2.39 Billion USD , up 43.79% from previous year.
  • Alcon Inc.'s latest quarterly EBITDA in 2024 Q2 was 639.85 Million USD , down -2.31% from previous quarter.
  • Alcon Inc. reported an annual EBITDA of 1.77 Billion USD in 2022, down -0.17% from previous year.
  • Alcon Inc. reported an annual EBITDA of 1.76 Billion USD in 2021, up 57.5% from previous year.
  • Alcon Inc. reported a quarterly EBITDA of 676 Million USD for 2024 Q1, up 18.15% from previous quarter.
  • Alcon Inc. reported a quarterly EBITDA of 261 Million USD for 2023 Q2, up 0.38% from previous quarter.

Annual EBITDA Chart of Alcon Inc. (2023 - 2015)

Historical Annual EBITDA of Alcon Inc. (2023 - 2015)

Year EBITDA EBITDA Growth
2023 2.39 Billion USD 43.79%
2022 1.77 Billion USD -0.17%
2021 1.76 Billion USD 57.5%
2020 1.11 Billion USD -7.5%
2019 1.25 Billion USD -10.64%
2018 1.35 Billion USD 12.0%
2017 1.21 Billion USD -4.97%
2016 1.16 Billion USD -20.09%
2015 1.56 Billion USD 0.0%

Peer EBITDA Comparison of Alcon Inc.

Name EBITDA EBITDA Difference
AptarGroup, Inc. 663.83 Million USD -260.485%
Baxter International Inc. 2.77 Billion USD 13.796%
Becton, Dickinson and Company 2.42 Billion USD 1.318%
Bausch + Lomb Corporation 586 Million USD -308.367%
Haemonetics Corporation 262.09 Million USD -813.029%
Envista Holdings Corp 171.1 Million USD -1298.616%
ResMed Inc. 1.6 Billion USD -49.534%
Teleflex Incorporated 792.26 Million USD -202.051%
Warby Parker Inc. -30.21 Million USD 8020.798%
West Pharmaceutical Services, Inc. 847.8 Million USD -182.264%